However, as MTHFD2 inhibitors cause cancer-specific replication stress, triggering the ATR-Chk1 signaling cascade, we observed a strong synergy between MTHFD2 inhibitors and ATR and Chk1 inhibitors. Here, MTHFD2 is linked to cancer.